Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Peripheral Nervous System Diseases 2Multiple Myeloma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Colorectal Neoplasms 2Wilms Tumor 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Oral Complications 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × Glutamine × Clear all
NCT02012608 2019-05-29

Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy

University of Arkansas

Phase 2 Terminated
14 enrolled 5 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡